NWBO - Northwest Bio gaining attention as investors await phase 3 GBM data

Interest in Northwest Bio (NWBO) has increased in recent days as some investors feel that the company is poised to release strong phase 3 data on its brain cancer treatment -- perhaps as soon as next month's American Society of Clinical Oncology ("ASCO") annual meeting.The double-blind, placebo-controlled trial of DCVax-L for glioblastoma multiforme enrolled 348 patients. The primary endpoint is progression-free survival.According to the company, the DCVax technology activates dendritic cells, considered the "master" cells of the body's immune system, to teach the immune system to fight cancers.Northwest also says that in clinical trials spanning more than a decade encompassing more than 1,000 treatment cycle, there has been no evidence of toxicities or severe adverse events associated with DCVax.Earlier this month, Northwest stated it is in a quiet period as it reviews data and analysis of the phase 3 trial.The same news release said that an application to certify a

For further details see:

Northwest Bio gaining attention as investors await phase 3 GBM data